Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

NCT02227459 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)

Interventions

DRUG: ND-L02-s0201 Injection

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]